Stock Evaluator: MaxCyte, Inc. (MXCT)

MaxCyte, Inc. MXCT

$1.18 -0.01 -0.84%
November 16, 2026 4:00:00 PM EST November 10, 2021 Volume: 1,959,184
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Life Sciences Tools & Services

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Commentary & Analysis


Financial Summary

Share Statistics MXCT Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $122.8 $3,632.0 24%
Shares Out (Mil) 106.8 107.2 63%
Institutional Ownership 97.8% 89.3% 75%
Float (Mil) 93.7 77.0 59%
Beta na 1.15 na
Avg Daily Volume (000s) 1,712 1,019 77%
Price Change
(52-week)
(21.2%) 82.0% 35%
Growth MXCT Industry
Median
Percentile
(All Stocks)
Sales (5yr) 4.7% 7.5% 35%
Net Income (5yr) (30.5%) (12.1%) 13%
EPS (5yr) (19.8%) 2.1% 14
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (27.7%) (14.9%) 22%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 3 2 3
Current EPS ($0.073) ($0.250) ($0.230)
Month Ago EPS ($0.073) ($0.277) ($0.247)
# Rev Up 0 1 0
# Rev Down 1 1 1
Three Months Ago EPS ($0.063) ($0.270) ($0.237)
Year/Year Chg (12.0%) (40.3%) (47.5%)
Financials MXCT Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $31 $811 16%
Net Income (TTM) (Mil) ($36) ($19) 19%
EPS (TTM) ($0.334) ($0.300) 30%
Operating Cash Flow (TTM) (Mil) ($23) $52 14%
Net Cash Flow (TTM) (Mil) $-0 $3 44%
Long-Term Debt (Q1) (Mil) $16 $252 31%
Enterprise Value (Q1) (Mil) $34 $3,486 15%
Valuation MXCT Industry
Median
Percentile
(All Stocks)
P/B 0.79 3.59 20%
P/E na 35.0 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 6.6 na
Ratios MXCT Industry
Median
Percentile
(All Stocks)
Gross Margin 81.0% 47.8% 89%
Net Margin (81.4%) (3.0%) 9%
ROA (17.6%) (5.4%) 21%
ROE (20.4%) (5.2%) 23%
Liabilities to Assets 14.0% 41.5% 9%
F-Score 4 5 33%

MaxCyte, Inc. did not pass any screens on 11/16/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors